Bill Gates invests $100 million in fighting Alzheimer’s

1 week ago kakp2 0

Bill Gates is investing $100 million of his personal fortune in research to find a cure for dementia and Alzheimer’s.

The billionaire Microsoft co-founder announced on Monday that he will give $50 million to the Dementia Discovery Fund, a venture capital fund that brings together industry and government to seek treatments for the brain-wasting disease.

The investment will be followed with another $50 million in a number of start-up ventures working in Alzheimer’s research, Gates said.

Both donations are personal investments, separate from Gates’ philanthropic Bill and Melinda Gates Foundation.

With rapidly rising numbers of people suffering from Alzheimer’s and other forms of dementia, the disease is taking a growing emotional and financial toll as people live longer, Gates said.

The billionaire Microsoft co-founder will invest $50 million in the Dementia Discovery Fund and $50 million in start-up ventures working in Alzheimer's research, he said on Monday

The billionaire Microsoft co-founder will invest $50 million in the Dementia Discovery Fund and $50 million in start-up ventures working in Alzheimer's research, he said on Monday

The billionaire Microsoft co-founder will invest $50 million in the Dementia Discovery Fund and $50 million in start-up ventures working in Alzheimer’s research, he said on Monday

‘It’s a huge problem, a growing problem, and the scale of the tragedy – even for the people who stay alive – is very high,’ he said.

Despite decades of scientific research, there is no treatment that can slow the progression of Alzheimer’s. Current drugs can do no more than ease some of the symptoms.

Gates said, however, that with focused and well-funded innovation, he’s ‘optimistic’ treatments can be found, even if they might be more than a decade away.

‘It’ll take probably 10 years before new theories are tried enough times to give them a high chance of success. So it’s very hard to hazard a guess (when an effective drug might be developed).

ALZHEIMER’S: FAST FACTS 

WHAT IS IT?

Alzheimer’s disease is a progressive, degenerative disease of the brain. 

A build-up of abnormal proteins causes nerve cells to die.

This disrupts the transmitters that carry messages, and causes the brain to shrink.

WHAT HAPPENS?

As brain cells die, the functions they provide are lost. 

That includes memory, orientation and the ability to think and reason. 

The progress of the disease is slow and gradual. 

On average, patients live five to seven years after diagnosis, but some may live for ten to 15 years.

EARLY SYMPTOMS:

  • Loss of short-term memory
  • Disorientation
  • Behavioral changes
  • Mood swings
  • Difficulties dealing with money
  • Difficulties making a phone call 
  • Difficulties following a TV show

LATER SYMPTOMS:

  • Severe memory loss, forgetting close family members, familiar objects or places
  • Becoming anxious and frustrated over inability to make sense of the world… 
  • …This can lead to aggressive behavior
  • Eventually lose ability to walk
  • May have problems eating and drinking 
  • The majority will eventually need 24-hour care 

HOW ALZHEIMER’S DIFFERS FROM NORMAL MEMORY LOSS:

With ordinary age-related forgetfulness, you will still remember details associated with the thing they’ve forgotten.

For example, you may forget your neighbor’s name in conversation, but you still know that person is your neighbor.

Alzheimer’s sufferers forget the entire context. 

‘I hope that in the next 10 years that we have some powerful drugs, but it’s possible that won’t be achieved.’

Dementia, of which Alzheimer’s is the most common form, affects close to 50 million people worldwide and is expected to affect more than 131 million by 2050, according to the non-profit campaign group Alzheimer´s Disease International.

The DDF, which was launched in 2015 and involves drugmakers GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer and Biogen Idec as well as the UK government, has already invested in at least nine start-up companies investigating potential ways to stop or reverse the biological processes that lead to dementia.

Gates told Reuters the additional $50 million would be put into start-ups working on some ‘less mainstream’ approaches to the disease, but said he had not yet identified these companies.

The philanthropist, whose usual focus is on infectious diseases in poorer countries, said Alzheimer’s disease caught his interest partly for personal reasons, and partly because it has so far proved such a tough nut to crack.

‘I know how awful it is to watch people you love struggle as the disease robs them of their mental capacity… It feels a lot like you’re experiencing a gradual death of the person that you knew,’ he said in a blog post about the dementia investments.

He added: ‘Some of the men in my family have suffered from Alzheimer’s, but I wouldn’t say that’s the sole reason’ (for this investment).

Through talking to experts in the field over the past year, Gates said he had identified five areas of need: Understanding better how Alzheimer’s unfolds, detecting and diagnosing it earlier, pursuing multiple approaches to trying to halt the disease, making it easier for people to take part in clinical trials of potential new medicines, and using data better.

‘My background at Microsoft and my (Gates) Foundation background say to me that a data-driven contribution might be an area where I can help add some value,’ he said.

Alongside the $50 million investment in DDF and the additional $50 million planned for start-ups, Gates said he would like to award a grant to build a global dementia data platform. 

This would make it easier for researchers to look for patterns and identify new pathways for treatment, he said.

dailymail.co.uk